The recommended starting dose of INLYTA® is 5 mg twice daily, taken orally, approximately 12 hours apart, with or without food.1 INLYTA® is available in 1 mg and 5 mg dose strengths to help dose adjustment.1
Dose increase or reduction is recommended based on individual safety and tolerability.
The dose of INLYTA® can be increased or decreased in the absence or presence of adverse reactions. If a patient tolerates the recommended starting dose of 5 mg twice daily with no adverse reactions greater than grade 2 for 2 consecutive weeks, you can step up to 7 mg twice daily, unless their blood pressure is greater than 150/90 mmHg or they’re taking antihypertensive treatment.1 The same criteria can then be applied to further increase their dose of INLYTA® to a maximum of 10 mg twice daily.1 Conversely, if adverse reactions develop, the dose of INLYTA® can be reduced to 3 mg twice daily and then to 2 mg twice daily if needed.1 Managing some adverse reactions may need temporary or permanent discontinuation and/or dose reduction of Inlyta® therapy.1
A short half-life could potentially lead to a relatively quick resolution of some adverse reactions following temporary treatment discontinuation.1–3
The half-life of INLYTA® is between 2.5 and 6.1 hours. Based on the short half-life of Inlyta, steady state is expected within 2 to 3 days of the initial dose.1
Once any adverse reactions subside, treatment with INLYTA® can be restarted, if necessary at a reduced dose.1,3 INLYTA® should be permanently discontinued if adverse events do not resolve.1
Legal Category: S1A
Further information is available upon request
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023